{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Orion+Corporation%2C+Orion+Pharma", "query": { "sponsor": "Orion Corporation, Orion Pharma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Orion+Corporation%2C+Orion+Pharma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-12T14:13:49.268Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02799602", "title": "Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Hormone-sensitive Prostate Cancer" ], "interventions": [ { "name": "BAY1841788 / darolutamide (ODM-201)", "type": "DRUG" }, { "name": "Standard ADT (androgen deprivation therapy)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1306, "start_date": "2016-11-30", "completion_date": "2023-04-11", "has_results": true, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-10-12T14:13:49.268Z", "location_count": 58, "location_summary": "Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02799602" }, { "nct_id": "NCT01429064", "title": "Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "ODM-201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orion Corporation, Orion Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 76, "start_date": "2011-06", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-02-20", "last_synced_at": "2026-10-12T14:13:49.268Z", "location_count": 4, "location_summary": "Wheat Ridge, Colorado • Norwich, Connecticut • Cleveland, Ohio + 1 more", "locations": [ { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01429064" }, { "nct_id": "NCT00099268", "title": "Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Carbidopa/levodopa/entacapone", "type": "DRUG" }, { "name": "Immediate release carbidopa/levodopa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "30 Years to 70 Years" }, "enrollment_count": 747, "start_date": "2004-09", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2012-04-23", "last_synced_at": "2026-10-12T14:13:49.268Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00099268" }, { "nct_id": "NCT07563738", "title": "A 2-part Phase 1/2 Open-label Trial on ODM-212", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mesothelioma", "Pancreatic Cancer", "NSCLC (Advanced Non-small Cell Lung Cancer)" ], "interventions": [ { "name": "ODM-212", "type": "DRUG" }, { "name": "Ipilimumab and nivolumab", "type": "DRUG" }, { "name": "Gemcitabine and nab-paclitaxel", "type": "DRUG" }, { "name": "sotorasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orion Corporation, Orion Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2026-03-27", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-12T14:13:49.268Z", "location_count": 2, "location_summary": "Irving, Texas • Fairfax, Virginia", "locations": [ { "city": "Irving", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07563738" }, { "nct_id": "NCT00348504", "title": "Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Heart Failure" ], "interventions": [ { "name": "levosimendan", "type": "DRUG" }, { "name": "dobutamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1300, "start_date": "2003-03", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2007-11-20", "last_synced_at": "2026-10-12T14:13:49.268Z", "location_count": 1, "location_summary": "Abbott Park, Illinois", "locations": [ { "city": "Abbott Park", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00348504" }, { "nct_id": "NCT03505021", "title": "Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "Levosimendan", "type": "DRUG" }, { "name": "Placebo for levosimendan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orion Corporation, Orion Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 496, "start_date": "2018-06-21", "completion_date": "2020-07-23", "has_results": true, "last_update_posted_date": "2022-05-11", "last_synced_at": "2026-10-12T14:13:49.268Z", "location_count": 48, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03505021" }, { "nct_id": "NCT06725758", "title": "A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "ODM-212", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orion Corporation, Orion Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 315, "start_date": "2023-10-26", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-12T14:13:49.268Z", "location_count": 8, "location_summary": "Los Angeles, California • Orange, California • St Louis, Missouri + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06725758" }, { "nct_id": "NCT02200614", "title": "Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer Non-Metastatic", "Castration-Resistant" ], "interventions": [ { "name": "Darolutamide (Nubeqa, BAY1841788)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1509, "start_date": "2014-09-12", "completion_date": "2021-06-14", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-10-12T14:13:49.268Z", "location_count": 55, "location_summary": "Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 48 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02200614" }, { "nct_id": "NCT00048425", "title": "Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure, Congestive" ], "interventions": [ { "name": "Levosimendan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2002-09", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2006-12-15", "last_synced_at": "2026-10-12T14:13:49.268Z", "location_count": 132, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048425" }, { "nct_id": "NCT06353386", "title": "Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "Opevesostat", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Fludrocortisone acetate", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2024-05-20", "completion_date": "2029-01-15", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-12T14:13:49.268Z", "location_count": 7, "location_summary": "La Jolla, California • Los Angeles, California • Miami, Florida + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06353386" } ] }